| Name | Title | Contact Details |
|---|
Good Shepherd Geriatric Ctr is a Mason City, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PepperPointe Partnerships is a dental service organization (DSO) that provides support with non-clinical tasks to dental practices, allowing practitioners to focus on providing excellent patient care. PepperPointe seeks to redefine what it means to be ...
Alivation puts you and your family`s health and well-being first. We do this by investing in the latest medical advancements and meticulously staffing the foremost experts in our industry. From basic behavioral health and family health services to in-depth treatments via transcranial magnetic stimulation therapy (TMS) and brain network monitoring, Alivation`s world-class facility and personal approach to your care is second to none. With a full-service pharmacy and research team on-site, Alivation is the only integrated healthcare clinic in the area that`s large enough to provide a high standard of unique care while being small enough to know our patients on a personal level.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Beacon Behavioral Health - Baton Rouge is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.